CAR T-Cell Therapy Market to Reach Valuation of USD 22.2 Billion By 2032: Astute Analytica [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
Despite high costs, research breakthroughs and growing approvals promise broader access and affordability. This revolutionary therapy offers a hopeful future in the fight against cancer. New Delhi, April 29, 2024 (GLOBE NEWSWIRE) -- The global CAR T-cell therapy market is on track for significant expansion, with projections indicating a surge from USD 2.1 billion in 2023 to over USD 22.2 billion by 2032 at a CAGR of 30% for the period 2024-2032. The rising tide of blood cancers is creating a strong market pull for CAR-T cell therapy. In the United States alone, nearly 185,000 new cases are expected in 2023, adding to the over 1.6 million people already living with or in remission from these diseases. This burden extends globally as well, with a steady rise in blood cancer cases since 1990, reaching over 1.3 million in 2019. The economic impact of blood cancers is equally concerning. By 2050, cancers are projected to cost the global economy a staggering $25.2 trillion, largely due
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- ArriVent Appoints John Hohneker, M.D., to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- ‘The 2024 Great Unbossing' Trending Among Middle Manager Careers In The Workplace [Forbes]Forbes
- Julius Bär Gruppe Leads Trio Of Swiss Dividend Stocks [Yahoo! Finance]Yahoo! Finance
- Oncodesign Precision Medicine and Navigo Proteins GmbH Sign a Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents [Yahoo! Finance]Yahoo! Finance
- Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 4/23/24 - Beat
NVS
Sec Filings
- 4/23/24 - Form 6-K
- 2/15/24 - Form S-8
- NVS's page on the SEC website